Akcea Therapeutics Inc (AKCA)

NASDAQ
18.17
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    18.13 - 18.17
  • 52 wk Range:
    18.13 - 18.17

AKCA Overview

Prev. Close
18.17
Day's Range
18.13-18.17
Revenue
22.38M
Open
18.15
52 wk Range
18.13-18.17
EPS
-0.85
Volume
0
Market Cap
1.85B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
294,127
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
101,759,772
Next Earnings Date
-
What is your sentiment on Akcea Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Akcea Therapeutics Inc News

Akcea Therapeutics Inc Analysis

Akcea Therapeutics Inc Company Profile

Akcea Therapeutics Inc Company Profile

Employees
294

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • watch out on November 5, $15.50 is target price
    0